China Resources teams up with Macquarie on $1.3B buy of GenesisCare


China Resources Group has teamed up with Australian investment bank Macquarie to buy a majority of cancer and cardio medical care provider GenesisCare in a transaction that will face regulatory approval on foreign investment.

The sale, which Reuters said was valued at $1.3 billion, sees private equity firm KKR selling its 45% stake in Sydney-based GenesisCare. Doctors and managers holding the remaining 55% stake that will be sold to China Resources and Macquarie in a fairly complex transaction that needs a nod from Australia's Foreign Investment Review Board and a shareholder vote.

China has encouraged private hospitals to fit out its medical system with newer services and take some of the patient demand strains away from a massive public hospital network.


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

China Resources, or CR, is expected to use its clout and experience gained through China hospital chain unit CR Healthcare to get GenesisCare to expand into China where access to cutting-edge therapies--particularly for cancer--lag because of an approval backlog.

At the same time, the sprawling CR Group is reportedly planning a $1 billion initial public offering in Hong Kong for unit CR Pharmaceutical.

- here's the story from Reuters

Related Articles:
China announces subsidies to wean more hospitals off drug markups


Suggested Articles

How is regulatory evolving to keep up with the digital innovation surge and consumer expectations? How can stakeholders wok better together?

Perrigo is treading water in its specialty drugs reinvention plan. Could a merger with another struggling drugmaker—à la Pfizer and Mylan—be the cure?

Companies routinely update analysts, but a new SEC order for tiny TherapeuticsMD offers a lesson—or reminder—about when to keep quiet.